Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF
In the September 17, 2024 issue of JACC, Valentin Fuster discusses a study on sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, which shows modest improvements in health status among patients with wors...
9 Sep 202410min
Effect of Evogliptin on the Progression of Aortic Valvular Calcification
In the September 17, 2024 issue of JACC, Dr. Jai Quan Song and colleagues explore whether the DPP-4 inhibitor, abrogating, can slow the progression of aortic valvular calcification. Although the prima...
9 Sep 202410min
Adverse Cardiovascular Outcomes in Patients with Obstructive Sleep Apnea and Obesity: Metabolic Surgery versus Usual Care
In this episode, Dr. Valentin Fuster reviews a groundbreaking study comparing metabolic surgery to traditional care for patients with obesity and obstructive sleep apnea. The research shows that metab...
9 Sep 202412min
JACC - September 17, 2024 Issue Summary
In this episode, Valentin Fuster reviews the September 17, 2024, JACC issue, highlighting pivotal studies on metabolic surgery's impact on cardiovascular risk in obstructive sleep apnea patients, and ...
9 Sep 202423min
RESHAPE-HF2 Trial Findings | ESC 2024
Dr. Marcus Anker, presenting at ESC, discussed the RESHAPE HF2 trial's findings on transcatheter edge-to-edge repair for secondary mitral regurgitation, published in JACC with Aakriti Gupta, MD, FACC,...
6 Sep 20246min
Effect of Screening for Undiagnosed Atrial Fibrillation and on Stroke Prevention | ESC Congress
Xiaoxi Yao, MPH, MS, PhD, FACC, JACC Associate Editor, interviews Renato Lopes, MD, PhD, FACC, author of the GUARD-AF trial published in JACC and presented at ESC Congress 2024.
5 Sep 202414min
Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024
Michelle M. Kittleson, MD, PhD, FACC, JACC Associate Editor and John A. Spertus, MD, MPH, FACC discuss the evaluation of the cardiac myosin inhibitor, aficamten, on patient-reported health status in p...
3 Sep 202421min
Insights from the SEQUOIA-HCM Trial and SEQUOIA-HCM CRM Substudy | ESC 2024
Michelle M. Kittleson, MD, PhD, FACC, JACC Associate Editor and John A. Spertus, MD, MPH, FACC discuss the evaluation of the cardiac myosin inhibitor, aficamten, on patient-reported health status in p...
3 Sep 202414min
